(Q51202531)
Statements
Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams (English)
C Bucci-Rechtweg
G Su
T F Hue
P Mesenbrink
K W Lyles
S Boonen
HORIZON Pivotal Fracture Trial and HORIZON Recurrent Fracture Trial Steering Committees